Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer

Sakunthala C Kudahetti, Gabrielle Fisher, Laurence Ambroisine, David Prowse, Michael W Kattan, Christopher S Foster, Henrik Møller, Tim Oliver, Anne Fletcher, Colin Cooper, Victor Reuter, Peter Scardino, Jack Cuzick, Daniel M Berney, Transatlantic Prostate Group

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

Treatment decisions are difficult in clinically localised prostate cancer and further biomarkers of aggressive behaviour are required. We investigated the hypothesis that the tissue expression of three cell cycle markers, Rb, p21 and p16, would provide helpful prognostic information in a well characterised series of prostate cancers which were clinically localised and treated conservatively.
Original languageEnglish
Pages (from-to)519-23
Number of pages5
JournalPlant Pathology
Volume42
Issue number6
DOIs
Publication statusPublished - 2010

Keywords

  • Cyclin-Dependent Kinase Inhibitor p16
  • Cyclin-Dependent Kinase Inhibitor p21
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Male
  • Neoplasm Staging
  • Prognosis
  • Prostatic Neoplasms
  • Retinoblastoma Protein
  • Tissue Array Analysis
  • Treatment Outcome
  • Tumor Markers, Biological

Cite this